Stanford University
Showing 261-280 of 383 Results
-
Neelam Goyal, MD
Clinical Associate Professor, Neurology & Neurological Sciences
Current Research and Scholarly InterestsDr. Goyal's research interests involve monitoring and managing the short and long-term toxicity of immunosuppressive agents used in the treatment of immune-mediated neuromuscular disorders. She is actively involved in a grant-supported project investigating steroid toxicity in patients with myasthenia gravis.
She also serves as the Wellbeing Co-Director for the Neurology Department, working on a grant-supported project aimed at mitigating the adverse impact of work on personal relationships. -
Or Gozani
Dr. Morris Herzstein Professor
Current Research and Scholarly InterestsWe study the molecular mechanisms by which chromatin-signaling networks effect nuclear and epigenetic programs, and how dysregulation of these pathways leads to disease. Our work centers on the biology of lysine methylation, a principal chromatin-regulatory mechanism that directs epigenetic processes. We study how lysine methylation events are generated, sensed, and transduced, and how these chemical marks integrate with other nuclear signaling systems to govern diverse cellular functions.
-
Erin Elizabeth Grady
Clinical Professor, Radiology - Rad/Nuclear Medicine
BioErin Grady, MD, CCD, FACNM, FSNMMI is a nuclear medicine physician at Stanford Hospital and Clinics in Stanford, California. She is actively involved nationally in the SNMMI in multiple capacities including as a Director-at-Large on the SNMMI Board of Directors, chair of the Nuclear Medicine Program Directors, a member of the General Nuclear Medicine Council board, co-chair of the Government Relations Committee and a longstanding member of the Coding and Reimbursement Committee. In addition, she is a past chair of the American Board of Nuclear Medicine and has served on the board of appeals panel, review committee and milestone development committee for Nuclear Medicine and milestone revision committee for Nuclear Radiology at the ACGME. Her areas of research interest include quality, education, radiopharmaceutical therapy and finding answers to clinical questions that arise during the course of practice. She is passionate about education in nuclear medicine, nuclear medicine’s future and is a staunch advocate for patients.
-
Peter Graham
Professor of Physics
Current Research and Scholarly InterestsWhat physics lies beyond the Standard Model and how can we discover it?
Professor Graham is broadly interested in theoretical physics beyond the Standard Model which often involves cosmology, astrophysics, general relativity, and even atomic physics. The Standard Model leaves many questions unanswered including the nature of dark matter and the origins of the weak scale, the cosmological constant, and the fundamental fermion masses. These clues are a guide to building new theories beyond the Standard Model. He recently proposed a new solution to the hierarchy problem which uses dynamical relaxation in the early universe instead of new physics at the weak scale.
Professor Graham is also interested in inventing novel experiments to discover such new physics, frequently using techniques from astrophysics, condensed matter, and atomic physics. He is a proposer and co-PI of the Cosmic Axion Spin Precession Experiment (CASPEr) and the DM Radio experiment. CASPEr uses nuclear magnetic resonance techniques to search for axion dark matter. DM Radio uses high precision magnetometry and electromagnetic resonators to search for hidden photon and axion dark matter. He has also proposed techniques for gravitational wave detection using atom interferometry.
Current areas of focus:
Theory beyond the Standard Model
Dark matter models and detection
Novel experimental proposals for discovering new physics such as axions and gravitational waves
Understanding results from experiments ranging from the LHC to early universe cosmology -
Stephan Graham
Welton Joseph and Maud L'Anphere Crook Professor of Applied Earth Sciences & by courtesy, of Geophysics & of Energy Science Engineering
Current Research and Scholarly InterestsSedimentary basin analysis; petroleum geology
-
Mark Granovetter
Joan B. Ford Professor
BioMark Granovetter's main interest is in the way people, social networks and social institutions interact and shape one another. He has written extensively on this subject, including his two most widely cited articles "The Strength of Weak Ties" (1973) and "Economic Action and Social Structure: The Problem of Embeddedness" (1985). In recent years, his focus has been on the social foundations of the economy, and he is working on a book entitled Society and Economy, to be published by Harvard University Press in two volumes. The first volume, Society and Economy: Framework and Principles,appeared in 2017. It is broadly theoretical, treating the role in the economy of social networks, norms, culture, trust, power, and social institutions. The second volume will use this framework to illuminate the study of such important topics as corruption, corporate governance, organizational form and the emergence of new industries such as the American electricity industry and the high-tech industry of Silicon Valley.
-
Philip Grant
Clinical Associate Professor, Medicine - Infectious Diseases
BioMy research focuses on antiretroviral therapy and complications of HIV including immune reconstitution inflammatory disease, osteoporosis, and cardiovascular disease.
-
Teodor Grantcharov
Professor of Surgery (General Surgery)
BioDr. Teodor Grantcharov completed his surgical training at the University of Copenhagen, and a doctoral degree in Medical Sciences at the University of Aarhus in Denmark.
Dr. Grantcharov is a Professor of Surgery at Stanford University and Associate Chief Quality Officer for Innovation and Safety at Stanford Healthcare.
Prior to joining Stanford, Dr. Grantcharov was a Professor of Surgery at the University of Toronto and Keenan Chair in Surgery at St. Michael’s Hospital in Toronto. He was the Founder of the International Centre for Surgical Safety – a multidisciplinary group of visionary scientists with expertise in design, human factors, computer- and data science, and healthcare research. He previously held Canada Research Chair in Simulation and Surgical Safety and was awarded the Queen Elizabeth II diamond jubilee medal for his contributions to clinical research and patient safety in Canada. Dr. Grantcharov was awarded the honorary fellowship of the Imperial College in London, the honorary fellowships of the Bulgarian, Danish and Brazilian surgical societies, the Spinoza Chair in Surgery from the University of Amsterdam and multiple national and international awards for his contributions to surgical education and surgical safety.
Dr. Grantcharov’s clinical interest is the area of minimally invasive surgery, while his academic focus is in the field of surgical innovation and patient safety. He has become internationally recognized as a leader in this area with his work on curriculum design, assessment of competence and impact of surgical performance on clinical outcomes. Dr. Grantcharov developed the surgical Black Box concept, which aims to transform the safety culture in medicine and introduce modern safety management systems in the high-risk operating room environment.
Dr. Grantcharov has more than 220 peer-reviewed publications and more than 200 invited presentations in Europe, South- and North America. He holds several patents and is the Founder of Surgical Safety Technologies Inc – an academic startup that commercializes the OR Black Box platform. He sits on numerous committees with Surgical Professional Societies in North America and Europe. -
Giorgio Gratta
Ray Lyman Wilbur Professor
BioGiorgio Gratta is a Professor of Physics at Stanford university where he is currently serving as chair of the Physics Department. Gratta is an experimentalist, with research interests in the broad area of the physics of fundamental particles and their interactions. While his career started with experiments at particle colliders, since at Stanford Gratta has tackled the study of neutrinos and gravity at the shortest distances. With two landmark experiments using neutrinos produced by nuclear reactors, made observations in the area of neutrino oscillations, and with one of them was first in reporting oscillations using artificial neutrinos and establishing the finite nature of neutrino masses. The same experiment was also first to detect neutrinos from the interior of our planet, providing a new tool for the Earth sciences. At a very different energy scale, Gratta and his group substantially advanced the techniques to detect ultra-high energy neutrinos in cosmic radiation, using acoustic signals in large bodies of water.
In more recent times, Gratta has led the development of liquid Xenon detectors in the search for the neutrinoless double beta decay, a nuclear decay that if observed would change our understanding of the quantum nature of neutrinos and help explaining the asymmetry between matter and antimatter in the universe. Gratta is currently the scientific leader of one of the three very large experiments on the subject, world-wide.
In a parallel development, Gratta’s group is studying new long range interactions (or an anomalous behavior of gravity) at distances below 50 micrometers. This is achieved with an array of different techniques, from optical levitation of microscopic particles in vacuum, to the use of Mössbauer spectroscopy and, most recently, neutron scattering on nanostructured materials. -
Dita Gratzinger
Professor of Pathology
Current Research and Scholarly InterestsI have research interests in the interaction of hematolymphoid neoplasia with the microenvironment. For example, I use a combination of immunohistochemistry, immunofluorescence and image analysis techniques to evaluate the mesenchymal stromal cell compartment in myelodysplastic syndrome (pre-leukemic bone marrow failure disorder). I also have interests in lymphoma vasculature and the tropism of lymphoma for specific types of vasculature.
-
Edward Graves
Associate Professor of Radiation Oncology (Radiation Physics) and, by courtesy, of Radiology (Molecular Imaging Program at Stanford)
Current Research and Scholarly InterestsApplications of molecular imaging in radiation therapy, development of hypoxia and radiosensitivity imaging techniques, small animal image-guided conformal radiotherapy, image processing and analysis.
-
Nathanael S. Gray
Krishnan-Shah Family Professor
BioNathanael Gray is the Krishnan-Shah Family Professor of Chemical and Systems Biology at Stanford, Co-Director of Cancer Drug Discovery Co-Leader of the Cancer Therapeutics Research Program, Member of Chem-H, and Program Leader for Small Molecule Drug Discovery for the Innovative Medicines Accelerator (IMA). His research utilizes the tools of synthetic chemistry, protein biochemistry, and cancer biology to discover and validate new strategies for the inhibition of anti-cancer targets. Dr. Gray’s research has had broad impact in the areas of kinase inhibitor design and in circumventing drug resistance.
Dr. Gray received his PhD in organic chemistry from the University of California at Berkeley in 1999 after receiving his BS degree with the highest honor award from the same institution in 1995. After completing his PhD, Dr. Gray was recruited to the newly established Genomics Institute of the Novartis Research Foundation (GNF) in San Diego, California. During his six year stay at GNF, Dr. Gray became the director of biological chemistry where he supervised a group of over fifty researchers integrating chemical, biological and pharmacological approaches towards the development of new experimental drugs. Some of the notable accomplishments of Dr. Gray’s team at GNF include: discovery of the first allosteric inhibitors of wild-type and mutant forms of BCR-ABL which resulted in clinical development of ABL001; discovery of the first selective inhibitors of the Anaplastic Lymphoma Kinase (ALK), an achievement that led to the development of now FDA-approved drugs such as ceritinib (LDK378) for the treatment of EML4-ALK expressing non-small cell lung cancer (NSCLC); and discovery that sphingosine-1-phosphate receptor-1 (S1P1) is the pharmacologically relevant target of the immunosuppressant drug Fingomilod (FTY720) followed by the development of Siponimod (BAF312), which is currently used for the treatment of multiple sclerosis.
In 2006, Dr. Gray returned to academia as a faculty member at the Dana Farber Cancer Institute and Harvard Medical School in Boston. There, he has established a discovery chemistry group that focuses on developing first-in-class inhibitors for newly emerging biological targets, including resistant alleles of existing targets, as well as inhibitors of well-validated targets, such as Her3 and RAS, that have previously been considered recalcitrant to small molecule drug development. Dr. Gray’s team developed covalent inhibitors of the T790M mutant of EGFR inspired the development of Osimertinib (AZD9291), now FDA approved for treatment of patients with relapsed lung cancer due to resistance to first generation EGFR inhibitors. Dr. Gray has also developed structure-based, generalized approaches for designing drugs to overcome one of the most common mechanisms of resistance observed against most kinase inhibitor drugs, mutation of the so-called "gatekeeper" residue, which has been observed in resistance to drugs targeting BCR-ABL, c-KIT and PDGFR.
In 2021, Dr. Gray joined Stanford University where he has joined the Stanford Cancer Institute, Chem-H and the Innovative Medicines Accelerator (IMA) to spur the development of prototype drugs.
These contributions have been recognized through numerous awards including the National Science Foundation’s Career award in 2007, the Damon Runyon Foundation Innovator award in 2008, the American Association for Cancer Research for Team Science in 2010 and for Outstanding Achievement in 2011 and the American Chemical Society award for Biological Chemistry in 2011, and the Nancy Lurie Marks endowed professorship in 2015 and the Paul Marks Prize in 2019, and the Hope Funds for Cancer Research in 2023.
